Topics

Safety and Tolerability of Omalizumab in Adults and Adolescents With Severe Allergic Asthma

2014-07-24 14:21:20 | BioPortfolio

Summary

This study will assess further the safety and tolerability of long-term treatment with omalizumab by extending omalizumab treatment by 1 year for those patients with allergic asthma who successfully completed study CIGE25011E2.

Study Design

Allocation: Non-Randomized, Control: Uncontrolled, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Conditions

Asthma

Intervention

Omalizumab

Status

Completed

Source

Novartis

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-07-24T14:21:20-0400

Clinical Trials [1526 Associated Clinical Trials listed on BioPortfolio]

Effects of Omalizumab Compared to Non-Omalizumab Treatment in Asthma Patients

The purpose of this study is effects of Omalizumab compared to non-Omalizumab treatment in the propensity-matched group on asthma exacerbation in asthma patients in Korea: a retrospective ...

Efficacy and Safety of Omalizumab in Patients With Severe Persistent Asthma

The purpose of this study is to determine the effect of omalizumab, compared to placebo, on clinically significant asthma exacerbation rates in adolescents and adults with asthma.

Omalizumab in Adult and Adolescent Patients With Severe Persistent Allergic Asthma

Omalizumab will be given as add-on treatment to optimized asthma therapy in patients with severe persistent asthma, who demonstrate inadequate asthma symptom control. Response to omalizuma...

Safety and Tolerability of Omalizumab in Patients With Mild to Moderate Asthma

This study will evaluate the safety and efficacy of omalizumab against asthma attacks in mild to moderate allergic asthma

Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With Persistent Allergic Asthma

This study is designed to investigate the use of omalizumab as a pretreatment for patients with persistent allergic asthma who are candidates for allergen immunotherapy (ie, allergy shots)...

PubMed Articles [995 Associated PubMed Articles listed on BioPortfolio]

Economic Impact and Clinical Outcomes of Omalizumab Add-On Therapy for Patients with Severe Persistent Asthma: A Real-World Study.

Omalizumab is a fully humanized monoclonal antibody indicated as add-on therapy to improve asthma control in patients with severe persistent allergic asthma.

Systemic reaction rates with omalizumab, subcutaneous immunotherapy, and combination therapy in children with allergic asthma.

For children with moderate-to-severe persistent allergic asthma, omalizumab is effective. However, it is expensive, and there are no current guidelines for discontinuation. Subcutaneous immunotherapy ...

The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma.

Mepolizumab and omalizumab are treatments for distinct but overlapping severe asthma phenotypes.

Quality of life in patients with allergic asthma on treatment with omalizumab.

Omalizumab is a monoclonal antibody that controls severe allergic asthma symptoms and reduces exacerbations.

IgE-Mediated Multimorbidities in Allergic Asthma and the Potential for Omalizumab Therapy.

Allergic asthma often coexists with different pathological conditions, called multimorbidities, that are mostly of allergic nature and share a common underlying inflammatory pathophysiological mechani...

Medical and Biotech [MESH] Definitions

An anti-IgE, recombinant, humanized monoclonal antibody which specifically binds to the C epsilon3 domain of IMMUNOGLOBULIN E, the site of high-affinity IgE receptor binding. It inhibits the binding of IgE to MAST CELLS and BASOPHILS to reduce the severity of the allergic response and is used in the management of persistent allergic ASTHMA.

Asthma attacks caused, triggered, or exacerbated by OCCUPATIONAL EXPOSURE.

Asthma attacks following a period of exercise. Usually the induced attack is short-lived and regresses spontaneously. The magnitude of postexertional airway obstruction is strongly influenced by the environment in which exercise is performed (i.e. inhalation of cold air during physical exertion markedly augments the severity of the airway obstruction; conversely, warm humid air blunts or abolishes it).

Drugs that are used to treat asthma.

A beta-adrenergic agonist used in the treatment of asthma and bronchospasms.

More From BioPortfolio on "Safety and Tolerability of Omalizumab in Adults and Adolescents With Severe Allergic Asthma"

Quick Search

Relevant Topics

Allergies
The term allergy is used to describe a response, within the body, to a substance, which is not necessarily harmful in itself, but results in an immune response and a reaction that causes symptoms and disease in a predisposed person, which in turn can cau...

Asthma
Asthma is caused by inflammation of small tubes, called bronchi, which carry air in and out of the lungs. If you have asthma, the bronchi will be inflamed and more sensitive than normal.  When you come into contact with something that irritates your...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...


Searches Linking to this Trial